ASPP2κ siRNA

ASPP2κ siRNA is an experimental small interfering RNA (siRNA) designed to selectively target and silence the ASPP2κ isoform, an oncogenic splice variant of the tumor suppressor Apoptosis Stimulating Protein of p53-2 (ASPP2). ASPP2κ is characterized by the loss of binding sites for p53, BCL-2, and NFκB, which contributes to drug resistance and tumor progression in hematological malignancies such as leukemia and multiple myeloma. By specifically targeting the unique fusion site of the ASPP2κ mRNA, this siRNA restores the proapoptotic function of the wild-type p53 pathway and sensitizes cancer cells to chemotherapy (e.g., melphalan) and proteasome inhibitors (e.g., bortezomib, carfilzomib). While primarily used as a research tool in preclinical cell and xenograft models, recent studies have explored medicinal-grade versions for potential therapeutic application.

Other names

ASPP2k siRNAASPP-2k siRNAASPP 2k siRNAASPP2 kappa siRNAASPP-2 kappa siRNAASPP 2 kappa siRNA